Cinedigm (CIDM) Competitors $3.11 +0.38 (+13.92%) (As of 11/11/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsTrends CIDM vs. BTX, ALFIW, and NLOKShould you be buying Cinedigm stock or one of its competitors? The main competitors of Cinedigm include Brooklyn ImmunoTherapeutics (BTX), Alfi (ALFIW), and NortonLifeLock (NLOK). These companies are all part of the "information" sector. Cinedigm vs. Brooklyn ImmunoTherapeutics Alfi NortonLifeLock Cinedigm (NASDAQ:CIDM) and Brooklyn ImmunoTherapeutics (NYSE:BTX) are both small-cap information companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking. Which has stronger valuation & earnings, CIDM or BTX? Brooklyn ImmunoTherapeutics has lower revenue, but higher earnings than Cinedigm. Cinedigm is trading at a lower price-to-earnings ratio than Brooklyn ImmunoTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCinedigm$72.33M8.04-$9.35M-$0.05-62.20Brooklyn ImmunoTherapeuticsN/AN/AN/A-$2.27-0.48 Which has more volatility & risk, CIDM or BTX? Cinedigm has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Brooklyn ImmunoTherapeutics has a beta of 4.61, suggesting that its stock price is 361% more volatile than the S&P 500. Is CIDM or BTX more profitable? Company Net Margins Return on Equity Return on Assets CinedigmN/A N/A N/A Brooklyn ImmunoTherapeutics N/A N/A N/A Does the media prefer CIDM or BTX? In the previous week, Brooklyn ImmunoTherapeutics had 1 more articles in the media than Cinedigm. MarketBeat recorded 1 mentions for Brooklyn ImmunoTherapeutics and 0 mentions for Cinedigm. Cinedigm's average media sentiment score of 0.00 equaled Brooklyn ImmunoTherapeutics'average media sentiment score. Company Overall Sentiment Cinedigm Neutral Brooklyn ImmunoTherapeutics Neutral Does the MarketBeat Community prefer CIDM or BTX? Cinedigm and Brooklyn ImmunoTherapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformCinedigmOutperform VotesNo VotesUnderperform Votes56100.00% Brooklyn ImmunoTherapeuticsOutperform VotesNo VotesUnderperform Votes94100.00% Do institutionals & insiders believe in CIDM or BTX? 8.0% of Cinedigm shares are owned by institutional investors. Comparatively, 26.0% of Brooklyn ImmunoTherapeutics shares are owned by institutional investors. 16.4% of Cinedigm shares are owned by company insiders. Comparatively, 20.5% of Brooklyn ImmunoTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryBrooklyn ImmunoTherapeutics beats Cinedigm on 5 of the 7 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Cinedigm News Delivered to You Automatically Sign up to receive the latest news and ratings for CIDM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CIDM vs. The Competition Export to ExcelMetricCinedigmMotion Picture and Video Production IndustryInformation SectorNASDAQ ExchangeMarket Cap$581.31M$581.31M$4.54B$8.93BDividend YieldN/AN/A3.69%4.02%P/E Ratio-62.20N/A8.0118.07Price / Sales8.048.047.1175.10Price / CashN/AN/AN/A36.30Price / BookN/AN/AN/A6.01Net Income-$9.35MN/AN/A$224.44M7 Day Performance14.76%14.76%1.96%1.48%1 Month Performance114.48%114.48%16.12%7.64%1 Year Performance182.73%182.73%30.52%32.93% Cinedigm Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CIDMCinedigmN/A$3.11+13.9%N/A+182.7%$581.31M$72.33M-62.20140BTXBrooklyn ImmunoTherapeuticsN/A$1.13+2.7%N/A-4.2%$66.47MN/A-0.50N/AGap UpALFIWAlfiN/A$0.00flatN/AN/A$0.00$200,684.000.0040NLOKNortonLifeLock1.0585 of 5 stars$30.37+2.8%N/A+58.4%$17.35B$2.82B21.24N/A Related Companies and Tools Related Companies BTX Competitors ALFIW Competitors NLOK Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CIDM) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cinedigm Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Cinedigm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
